Cash Flow Statement (Annual)

CVSI / CV Sciences, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss -90 -46 -2,300 -1,312 -12,233 -14,141
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
  Depreciation Depletion And Amortization - - - 934 1,012 1,053
  Depreciation And Amortization - 0 767 934 - -
  Amortization Of Debt Discount Premium - 0 211 589 - -
  Amortization Of Financing Costs - - - 0 265 289
  Stock Issued Pursuant To Employment Agreement - - 6 42 0 -
  Provision For Doubtful Accounts - 0 400 -300 2,655 59
  Amortization Of Derivative Liability Discount - - - - 0 408
  Income Loss From Equity Method Investments - 0 -311 -39 0 -
  Amortization Of Beneficial Conversion Feature Of Convertible Debt - - - 589 574 0
  Share Based Compensation - - 0 7,916 5,720 2,733
  Restricted Shares Issued Under Employment Agreement Amount - 0 -6 - - -
  Increase Decrease In Operating Capital
    Increase Decrease In Prepaid Expense -2 2 174 353 -76 -
    Increase Decrease In Prepaid Deferred Expense And Other Assets - 0 474 -1,215 -520 -61
    Increase Decrease In Inventories - 0 2,128 9,193 2,468 -1,309
    Increase Decrease In Accounts Receivable - 0 1,744 -1,206 588 -70
    Increase Decrease In Accounts Payable 20 -20 25 191 113 -
    Increase Decrease In Other Accrued Liabilities - 0 223 179 418 -
    Net Cash Provided By Used In Operating Activities Continuing Operations - -64 -4,879 -6,712 -4,208 -2,054
    Net Cash Provided By Used In Investing Activities
      Cash Acquired From Acquisition - 0 51 0 - -
      Payments To Acquire Property Plant And Equipment - 0 227 449 114 17
      Payments For Proceeds From Longterm Investments - 0 950 0 - -
      Payments To Acquire Equity Method Investments - 0 750 0 - -
      Net Cash Provided By Used In Investing Activities Continuing Operations - 0 -1,876 -1,384 -1,743 853
      Net Cash Provided By Used In Financing Activities
        Proceeds From Repayments Of Related Party Debt - 63 0 - - -
        Proceeds From Related Party Debt 21 63 6,192 - - -
        Repayment Of Loan To Roen Ventures - 0 100 - - -
        Repayments Of Related Party Debt 0 0 0 0 0 -
        Common Stock To Be Issued Cash Flow - 0 175 0 - -
        Proceeds From Issuance Of Common Stock 29 - 2,731 8,248 2,520 0
        Proceeds From Issuance Or Sale Of Equity - 0 2,731 - - -
        Net Cash Provided By Used In Financing Activities Continuing Operations - 63 8,998 8,155 4,167 1,740
        Proceeds From Notes Payable - - 6,192 0 178 -
        Cash And Cash Equivalents Period Increase Decrease -30 -1 2,243 59 - -
        Repayments Of Notes Payable - - 100 92 39 174
        Proceeds From Convertible Debt - - - 0 1,508 1,975
        Cash And Cash Equivalents At Carrying Value 1 - 2,244 2,302 - -
        Supplemental Cash Flow Information
          Income Taxes Paid - 0 0 0 0 22
          Interest Paid 0 3 0 187 0 338
          Noncash Investing And Financing Items
            Value Of Debt Discount - 0 800 0 - -
            Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables - - 396 0 - -
            Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory - - 345 0 - -
            Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets - - 1,261 0 - -
            Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment - - 1 0 - -
            Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets - - 4,110 0 - -
            Goodwill - - 1,856 1,856 4,644 2,788
            Stock Issued During Period Value Acquisitions - 0 7,070 0 1,150 -
            Goodwill Non Cash Transaction - - 1,856 0 - -
            Goodwill Acquired In Canx Acquisition - - - 0 2,538 0
            Conversion Of Convertible Promissory Notes And Accrued Interest To Common Stock - - - - 765 583
            Amount Due To Phytosphere Agreement - - -1,315 0 - -
            Intangible Asset Acquired In Canx Acquisition - - - 0 3,907 0
            Value Of Warrants Issued With Unsecured Promissory Note - - - - 0 267
            Contingent Consideration On Canx Acquisition - - - 0 -3,739 0
            Value Of Embedded Derivative At Inception - - - - 0 370
            Conversion Of Line Of Credit Roen Ventures Llc To Common Stock - - 0 6,000 0 -
            Common Shares Issued On Canx Acquisition - - - 0 -1,150 0
            Inventory Returned In Satisfaction Of Note Receivable - - - - 0 68
            Conversion Of Accounts Receivable To Note Receivable - - 0 -600 0 -
            Deferred Tax Liability On Canx Acquisition - - - 0 -1,556 0
            Contingent Equity Consideration Issued To Can X - - - - 0 0
            Beneficial Conversion Feature On Convertible Debt - - - 0 -612 0
            Common Stock To Be Issued Other - - 0 -175 0 -
            Common Stock Received In Exchange For Sale Of Investment - - 0 8,300 0 -
            Shares Cancelled Upon Foreclosure Of Notes Receivable Value - - - - 0 60
            Conversion Of Convertible Promissory Notes - - - 0 765 -
            Accrual For Required Stock Redemption - - - - 0 75
            Common Stock Received In Exchange For Payment On Notes Receivable - - - 0 242 0
            Purchase Of Insurance Through Issuance Of Note Payable - - - - 0 161
            Common Stock Issued For Services - - - 0 -88 0
            Common Stock Issued For Accrued Interest - - - 0 -13 0
        Issuance Of Note Payable From Vendor - - - - 178 0
        Repayments Of Other Debt - - - 92 0 -
        Proceeds From Issuance Of Unsecured Debt - - - - 0 801
        Payments For Proceeds From Previous Acquisition - - - - 0 250
        Repayments Of Convertible Debt - - - - 0 612
        Cash Period Increase Decrease - - - 59 -1,784 539
        Cash - - - - 518 782
        Cash And Restricted Cash - - - - - 1,057
      Payments To Acquire Businesses Gross - - - 0 250 0
      Payments To Acquire Notes Receivable - - 0 1,200 2,003 0
      Repayment Of Principal On Note Receivable - - 0 265 - -
      Proceeds From Collection Of Notes Receivable Related Party - - - - 0 859
      Proceeds From Sale Of Property Plant And Equipment - - - - 0 10
      Repayment Of Notes Receivable - - - 265 624 -
      Proceeds From Collection Of Notes Receivable - - - - 624 0
    Increase Decrease In Prepaid Expenses Other - - - - -520 0
    Increase Decrease In Accounts Payable And Accrued Liabilities - - - - 531 -355
  Gain Loss On Sale Of Equity Investments - - 0 7,899 0 -
  Note Receivable Issued On Litigation Settlement - - - 0 600 0
  Increase Decrease In Other Operating Assets - - 0 -35 0 -
  Issuance Of Stock And Warrants For Services Or Claims - - - 0 328 541
  Increase Decrease In Interest Payable Net - - - - 0 128
  Gain Loss On Disposition Of Assets - - - - 0 -9
  Gain On Collection Of Related Party Notes Receivable - - - - 0 379
  Allowance For Doubtful Accounts Receivable Period Increase Decrease - - - -300 2,655 -
  Derivative Gain Loss On Derivative Net - - - - 0 147
  Inventory Write Down - - - - 0 3,562
  Goodwill And Intangible Asset Impairment - - 0 0 0 2,747

Related News Stories

Top-Performing Marijuana Stocks Of December

2017-12-28 seekingalpha
December has seen the culmination of at least 2 distinct catalysts propel several leading marijuana stocks much higher before the end of the year. (48-1)

CV Sciences, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-10 seekingalpha
The following slide deck was published by CV Sciences, Inc. in conjunction with their 2017 Q3 earnings call. (3-1)

CV Sciences' (CVSI) Management on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Greetings and welcome to CV Sciences’ 2017 Third Quarter Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Remind you that this conference is being recorded. (9-0)

CV Sciences Takes Aim at Smokeless Tobacco Addiction with CBD-Based Therapy

2017-10-17 accesswire
SANTA MONICA, CA / ACCESSWIRE / October 17, 2017 / According to the Centers for Disease Control and Prevention, tobacco use causes almost six million deaths annually, with that number expected to climb to eight million by 2030 based on current trends. In the U.S. alone, about one in five deaths, or approximately 1,300 deaths every day, are the result of cigarette smoking, making it a leading cause of preventable death. (3-1)

CUSIP: 126654102